LTCH vs. TOI, ORGN, QSI, MYPS, SHCR, REZI, LEV, CPS, AEVA, and CVGI
Should you be buying Latch stock or one of its competitors? The main competitors of Latch include Oncology Institute (TOI), Origin Materials (ORGN), Quantum-Si (QSI), PLAYSTUDIOS (MYPS), Sharecare (SHCR), Resideo Technologies (REZI), Lion Electric (LEV), Cooper-Standard (CPS), Aeva Technologies (AEVA), and Commercial Vehicle Group (CVGI).
Oncology Institute (NASDAQ:TOI) and Latch (NASDAQ:LTCH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.
Latch has a net margin of 0.00% compared to Latch's net margin of -20.28%. Oncology Institute's return on equity of 0.00% beat Latch's return on equity.
36.9% of Oncology Institute shares are owned by institutional investors. Comparatively, 0.4% of Latch shares are owned by institutional investors. 9.5% of Oncology Institute shares are owned by insiders. Comparatively, 27.5% of Latch shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Oncology Institute presently has a consensus price target of $2.25, indicating a potential upside of 355.28%. Given Latch's higher probable upside, analysts clearly believe Oncology Institute is more favorable than Latch.
Latch received 5 more outperform votes than Oncology Institute when rated by MarketBeat users. However, 66.67% of users gave Oncology Institute an outperform vote while only 27.27% of users gave Latch an outperform vote.
Oncology Institute has higher revenue and earnings than Latch.
In the previous week, Oncology Institute had 4 more articles in the media than Latch. MarketBeat recorded 4 mentions for Oncology Institute and 0 mentions for Latch. Latch's average media sentiment score of 0.59 beat Oncology Institute's score of 0.00 indicating that Oncology Institute is being referred to more favorably in the media.
Oncology Institute has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Latch has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500.
Summary
Oncology Institute beats Latch on 8 of the 15 factors compared between the two stocks.
Get Latch News Delivered to You Automatically
Sign up to receive the latest news and ratings for LTCH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LTCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
